Arcus Biosciences, Inc.

Arcus Biosciences, Inc.

RCUSNYSE / NASDAQHealthcareMid cap

$15.62-$0.16 (-1.0%)

Last close · Data as of Nov 20, 2026

Market cap
$3.1B
P/E
-8.8x
EV / EBITDA
-8.9x
Revenue
$247.0M
Net margin
-142.9%
ROCE
-42.5%

-26.4% over the last year

Arcus Biosciences, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-34.2%
3M
-47.1%
6M
-34.2%
1Y
-26.4%
5Y
-67.2%

52-week range

Day change -$0.16 (-1.0%) from $16 to $16 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in RCUS, bought on each weekday since 2021.

News & filings

What Arcus Biosciences filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 353 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 4.36 times current liabilities.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.

Read moreShow less

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Sector
Healthcare
Shares outstanding
125.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$3.1B
P/E
-8.8x
P/B
4.9x
EV / EBITDA
-8.9x
EV / Sales
12.1x
P/S
12.6x
52-week high
$31.57
52-week low
$15.62

Profitability

Operating margin
-156.3%
Net margin
-142.9%
EBITDA margin
-135.6%
ROE
-55.9%
ROCE
-42.5%
ROA
-31.0%
Asset turnover
0.22

Growth

Revenue
$247.0M
Revenue growth, 1Y
-4.3%
Revenue CAGR, 3Y
30.2%
Net profit growth, 1Y
24.7%
Free cash flow
-$484.0M

Solvency

Current ratio
4.36
Debt / Equity
0.18
Debt / Assets
0.10
CFO / Net profit
1.37
Cash / Market cap
7.1%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$247.0M
Gross profit$247.0M
Operating expenses$633.0M
Research and development$523.0M
Selling, general and administrative$110.0M
Operating income-$386.0M
Interest and other$33.0M
Pretax income-$353.0M
Tax and other$0.00
Net income-$353.0M

Revenue and net profit

Revenue fell 4.3% in FY2025; net profit is the dashed line.

Arcus Biosciences, Inc. revenue and net profit by fiscal year
Arcus Biosciences, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$112.0M-$267.0M
FY2023$117.0M-$307.0M
FY2024$258.0M-$283.0M
FY2025$247.0M-$353.0M

Cash flows

FY2025: -$482.0M from operations, -$484.0M free after investment (dashed).

Arcus Biosciences, Inc. operating and free cash flow by fiscal year
Arcus Biosciences, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$438.0M$432.0M
FY2023-$306.0M-$330.0M
FY2024-$170.0M-$176.0M
FY2025-$482.0M-$484.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$247.0M-4.3%1Y
EBITDA
-$335.0M
Net profit
-$353.0M
Cash from operations
-$482.0M
Free cash flow
-$484.0M
Revenue CAGR, 3Y
30.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$247.0M-$335.0M-$353.0M-$484.0M-55.9%-4.3%+24.7%

Monthly returns

Month-by-month returns of RCUS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.1B
Liabilities$508.0M
Equity$631.0M
Retained earnings-$1.5B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; RCUS highlighted.

P/E against peers

RCUS has no positive P/E; the peer median is 21.8x.

Not shown (no positive earnings and no EV / Sales): Arcus Biosciences, Inc., Supernus Pharmaceuticals, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Arcus Biosciences, Inc.RCUSthis company$3.1B-8.8x4.9x-55.9%-8.9x
ACADIA Pharmaceuticals Inc.ACAD$3.7B9.5x3.0x31.9%30.8x
Organon & Co.OGN$3.5B18.8x4.7x24.9%9.0x
ICU Medical, Inc.ICUI$3.4B4607.1x1.6x0.0%14.7x
Concentra Group Holdings Parent, Inc.CON$3.2B19.2x8.1x42.3%12.7x
Integer Holdings CorporationITGR$3.1B30.6x1.8x5.9%15.2x
National HealthCare CorporationNHC$2.9B24.5x2.7x11.2%13.7x
Privia Health Group, Inc.PRVA$2.7B117.5x3.7x3.1%50.4x
Supernus Pharmaceuticals, Inc.SUPN$2.6B-67.3x2.4x-3.6%58.9x
Peer median—21.8x2.9x8.6%15.0x

Year-to-date ROI

RCUS since 1 January, against earlier years.

Historical volatility

RCUS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Arcus Biosciences, Inc. operating margin by fiscal year
Arcus Biosciences, Inc. operating margin by fiscal year
DateOperating margin
FY2022-250.0%
FY2023-290.6%
FY2024-120.2%
FY2025-156.3%
LineFY2025
Operating expensesOperating Expense$633.0M
Research and developmentResearch And Development$523.0M
Total expensesTotal Expenses$633.0M
Pretax incomePretax Income-$353.0M

Learn while you research

Academy chapters picked for Arcus Biosciences, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →